Logo image of IMGN

ImmunoGen Inc (IMGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMGN - US45253H1014 - Common Stock

31.23 USD
0 (0%)
Last: 2/9/2024, 8:00:02 PM
31.24 USD
+0.01 (+0.03%)
After Hours: 2/9/2024, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMGN. IMGN was compared to 530 industry peers in the Biotechnology industry. While IMGN seems to be doing ok healthwise, there are quite some concerns on its profitability. IMGN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IMGN has reported negative net income.
In the past year IMGN has reported a negative cash flow from operations.
In the past 5 years IMGN always reported negative net income.
IMGN had a negative operating cash flow in each of the past 5 years.
IMGN Yearly Net Income VS EBIT VS OCF VS FCFIMGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.94%, IMGN belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
IMGN has a better Return On Equity (-13.09%) than 89.06% of its industry peers.
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROIC N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMGN Yearly ROA, ROE, ROICIMGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K -1.5K

1.3 Margins

IMGN has a better Gross Margin (98.61%) than 98.32% of its industry peers.
The Profit Margin and Operating Margin are not available for IMGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMGN Yearly Profit, Operating, Gross MarginsIMGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

IMGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMGN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, IMGN has a worse debt to assets ratio.
IMGN Yearly Shares OutstandingIMGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
IMGN Yearly Total Debt VS Total AssetsIMGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

IMGN has an Altman-Z score of 18.14. This indicates that IMGN is financially healthy and has little risk of bankruptcy at the moment.
IMGN has a better Altman-Z score (18.14) than 90.91% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that IMGN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.16, IMGN is not doing good in the industry: 68.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 18.14
ROIC/WACCN/A
WACC11.02%
IMGN Yearly LT Debt VS Equity VS FCFIMGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M -200M 300M

2.3 Liquidity

A Current Ratio of 5.69 indicates that IMGN has no problem at all paying its short term obligations.
With a Current ratio value of 5.69, IMGN perfoms like the industry average, outperforming 56.57% of the companies in the same industry.
IMGN has a Quick Ratio of 5.65. This indicates that IMGN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IMGN (5.65) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 5.65
IMGN Yearly Current Assets VS Current LiabilitesIMGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.20% over the past year.
The Revenue has grown by 200.63% in the past year. This is a very strong growth!
Measured over the past years, IMGN shows a decrease in Revenue. The Revenue has been decreasing by -1.17% on average per year.
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%

3.2 Future

The Earnings Per Share is expected to grow by 32.99% on average over the next years. This is a very strong growth
Based on estimates for the next years, IMGN will show a very strong growth in Revenue. The Revenue will grow by 69.78% on average per year.
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMGN Yearly Revenue VS EstimatesIMGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B
IMGN Yearly EPS VS EstimatesIMGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

IMGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
IMGN is valuated quite expensively with a Price/Forward Earnings ratio of 81.49.
93.94% of the companies in the same industry are more expensive than IMGN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 24.01. IMGN is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 81.49
IMGN Price Earnings VS Forward Price EarningsIMGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMGN Per share dataIMGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

IMGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IMGN's earnings are expected to grow with 44.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.06%
EPS Next 3Y44.14%

More info and screens

0

5. Dividend

5.1 Amount

IMGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ImmunoGen Inc

NASDAQ:IMGN (2/9/2024, 8:00:02 PM)

After market: 31.24 +0.01 (+0.03%)

31.23

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-09 2024-02-09/amc
Earnings (Next)04-26 2024-04-26/amc
Inst Owners0.16%
Inst Owner Change0%
Ins Owners0.43%
Ins Owner Change0%
Market Cap8.72B
Revenue(TTM)287.70M
Net Income(TTM)-73.50M
Analysts70.53
Price Target31.69 (1.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.82%
Min EPS beat(2)85.91%
Max EPS beat(2)119.72%
EPS beat(4)4
Avg EPS beat(4)66.67%
Min EPS beat(4)23.99%
Max EPS beat(4)119.72%
EPS beat(8)6
Avg EPS beat(8)47.51%
EPS beat(12)10
Avg EPS beat(12)59.04%
EPS beat(16)13
Avg EPS beat(16)56.88%
Revenue beat(2)2
Avg Revenue beat(2)36.59%
Min Revenue beat(2)4.48%
Max Revenue beat(2)68.71%
Revenue beat(4)4
Avg Revenue beat(4)86.57%
Min Revenue beat(4)4.48%
Max Revenue beat(4)138.97%
Revenue beat(8)7
Avg Revenue beat(8)54.29%
Revenue beat(12)8
Avg Revenue beat(12)38.51%
Revenue beat(16)11
Avg Revenue beat(16)32.28%
PT rev (1m)0.02%
PT rev (3m)34.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.27%
EPS NY rev (1m)6.14%
EPS NY rev (3m)223.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)7.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 81.49
P/S 30.32
P/FCF N/A
P/OCF N/A
P/B 15.53
P/tB 15.53
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.38
Fwd EY1.23%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.03
BVpS2.01
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.61%
FCFM N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.3%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.69
Quick Ratio 5.65
Altman-Z 18.14
F-Score4
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)63.67%
Cap/Depr(5y)66.52%
Cap/Sales(3y)1.33%
Cap/Sales(5y)3.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%
EBIT growth 1Y59.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.66%
EBIT Next 3Y43.02%
EBIT Next 5Y35.85%
FCF growth 1Y-71.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.08%
OCF growth 3YN/A
OCF growth 5YN/A

ImmunoGen Inc / IMGN FAQ

Can you provide the ChartMill fundamental rating for ImmunoGen Inc?

ChartMill assigns a fundamental rating of 3 / 10 to IMGN.


What is the valuation status for IMGN stock?

ChartMill assigns a valuation rating of 3 / 10 to ImmunoGen Inc (IMGN). This can be considered as Overvalued.


What is the profitability of IMGN stock?

ImmunoGen Inc (IMGN) has a profitability rating of 2 / 10.


Can you provide the financial health for IMGN stock?

The financial health rating of ImmunoGen Inc (IMGN) is 4 / 10.


Can you provide the expected EPS growth for IMGN stock?

The Earnings per Share (EPS) of ImmunoGen Inc (IMGN) is expected to grow by 108.78% in the next year.